Monte Rosa Therapeutics, Inc. GLUE Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s debt-to-equity?
- Monte Rosa Therapeutics, Inc. (GLUE) reported debt-to-equity of 0.1× in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s debt-to-equity decreased by 50.8% year-over-year, from 0.2× to 0.1×.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s debt-to-equity?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s debt-to-equity has grown at a 67.6% compound annual growth rate (CAGR), from 0× to 0.2×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.